mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
about
Current Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionEmpowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapyRecombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyondCan immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?The notorious R.N.A. in the spotlight - drug or target for the treatment of diseaseA dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication.Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapyInduction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells.Decreased HIV-specific T-regulatory responses are associated with effective DC-vaccine induced immunitySafety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial.Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells.Human dendritic cell subsets in vaccination.Dendritic cell dysregulation during HIV-1 infection.Dendritic cell based vaccines for HIV infection: the way ahead.A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugsmRNA transcript therapy.Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation.New challenges in therapeutic vaccines against HIV infection.From the RNA world to the clinic.Lipoplexes carrying mRNA encoding Gag protein modulate dendritic cells to stimulate HIV-specific immune responses.Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease.Immunomodulatory Nanomedicine.Interleukin-12p70 expression by dendritic cells of HIV-1-infected patients fails to stimulate gag-specific immune responses.Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune ResponseNucleoside Modified mRNA Vaccines for Infectious Diseases.GMP-Grade mRNA Electroporation of Dendritic Cells for Clinical Use.Synthetic mRNA: Production, Introduction into Cells, and Physiological Consequences.Generation and Cryopreservation of Clinical Grade Wilms' Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy.Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load.How Might We Cure HIV?A new developing class of gene delivery: messenger RNA-based therapeutics.Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.mRNA vaccines - a new era in vaccinology.Electroporation of mRNA as Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.Advances in dendritic cell immunotherapies for HIV-1 infection.
P2860
Q26775082-C7CBB996-795A-4BD3-A7A4-6F2078C2C6B5Q26781175-722EC7CB-44C1-4C37-9BAA-7B485C224A0CQ26861563-1AE319DA-C60A-4C7C-A9B2-1DBAD71D4981Q26865388-DF428185-65B2-455C-9043-E796FB59B31BQ33739733-B2B3373E-7E11-4047-919B-F18BC8D07CC1Q34646987-793D75BC-175D-411E-9DFA-42381E4938EAQ34749218-6F2D82E4-0C26-4640-9CEF-968271E5F817Q34796892-0D3B0263-C2A9-4C01-96A2-20053A262577Q35224581-85C481FC-837A-4052-8369-8C562D46BAD2Q37381097-600EF9EB-5FAC-4344-8794-6EFCB70CCBE4Q38059499-4572B905-AC06-4E57-8240-57CEF71B99C9Q38110971-A7AE496B-9DC8-4268-8016-5D900F39A7A1Q38114911-6A8B9283-AE74-43E9-B929-4339C3A2FCFEQ38126373-829DCDBC-6DF4-41D6-BFE3-68961C2C34B3Q38206520-AC628C19-E343-4B31-B5F6-B7DF0FDBCBB9Q38264088-69CD91B3-BB18-4E0E-8BA9-B971D31756D7Q38296086-9A037660-4949-4645-BD50-F36B51697513Q38692205-8D5A40EE-EC65-4217-B27F-6FD8CBEF6592Q38851919-E415B968-4704-41A9-A0AE-4C8E477AF75DQ38965589-72A55E92-9D55-419B-AB63-573D9B234996Q39027005-9884279B-2B8E-4817-BA50-AAAD71DA8AD3Q39224331-56F661E1-0729-4076-A470-CBF42ADE2768Q39550595-9B1767BF-00C8-4EE9-8F96-0C365234AACCQ39791507-10C3E633-4E83-4700-BCCF-43C2AC1AE8B5Q40405926-AC3650C8-68B7-4C7B-A7CE-3EBEF04CC205Q40654956-0645E177-F0D1-4781-88CE-FCA331DCA95AQ40654970-97929E3D-4508-4252-8179-C6EF45D6A3CFQ40733554-342E063C-14C2-4894-BE12-37A2DBB4A4C1Q42205079-CFD189AF-A7E1-47CA-A2EA-9E8A31CD609DQ42227337-8120085F-87EB-4FB5-9718-FB9EFB600783Q45873514-88878952-DF7B-43B2-89D8-791EF79032E2Q47674203-6CE16649-F2D7-49D0-B97B-A68BBB641E6DQ47736893-236AAAF0-7A4F-4E7F-8BE1-F8648A69625CQ50035982-560182D3-BFC8-4F9F-BF52-D12BF8D87336Q51217825-C842D2A5-CF3D-41B1-9C6C-81B2017B0FF0
P2860
mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
mRNA-based dendritic cell vacc ...... es in HIV-1-infected patients.
@en
mRNA-based dendritic cell vacc ...... es in HIV-1-infected patients.
@nl
type
label
mRNA-based dendritic cell vacc ...... es in HIV-1-infected patients.
@en
mRNA-based dendritic cell vacc ...... es in HIV-1-infected patients.
@nl
prefLabel
mRNA-based dendritic cell vacc ...... es in HIV-1-infected patients.
@en
mRNA-based dendritic cell vacc ...... es in HIV-1-infected patients.
@nl
P2093
P50
P1433
P1476
mRNA-based dendritic cell vacc ...... ses in HIV-1-infected patients
@en
P2093
Ann Van De Velde
Ellen Van Gulck
Erika Vlieghe
Guido Vanham
Herman Goossens
Johnsson Wong
Liesbet Mertens
Marc Vekemans
Nathalie Cools
Sébastien Anguille
P356
10.1097/QAD.0B013E32834F33E8
P407
P577
2012-02-01T00:00:00Z